Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “TAS 102”

113 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 113 results

Testing effectiveness (Phase 2)Study completedNCT03686488
What this trial is testing

TAS 102 in Combination With Ramucirumab in Advanced, Refractory Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma

Who this might be right for
Gastric AdenocarcinomaGastroesophageal Junction AdenocarcinomaGastric Cancer
H. Lee Moffitt Cancer Center and Research Institute 23
Testing effectiveness (Phase 2)Study completedNCT02860546
What this trial is testing

A Study Evaluating TAS-102 Plus Nivolumab in Patients With MSS CRC

Who this might be right for
Refractory Metastatic Colorectal Cancer
Taiho Oncology, Inc. 18
Testing effectiveness (Phase 2)UnknownNCT05029102
What this trial is testing

TAS-102 and Anlotinib in ≥3 Lines mGC

Who this might be right for
Gastric Cancer
Zhejiang University 45
Testing effectiveness (Phase 2)Active Not RecruitingNCT05608044
What this trial is testing

Botensilimab and Balstilimab for the Treatment of Colorectal Cancer

Who this might be right for
Metastatic Colorectal Cancer
Agenus Inc. 234
Testing effectiveness (Phase 2)Study completedNCT02920476
What this trial is testing

TAS-102 in Previously Treated Unresectable or Metastatic Squamous Cell Lung Carcinoma (UF-STO-LUNG-003)

Who this might be right for
Squamous Cell Lung Carcinoma
University of Florida 4
Testing effectiveness (Phase 2)Not Yet RecruitingNCT05364489
What this trial is testing

Efficacy, Safety and Exploratory Clinical Study of Bevacizumab Combined With Oxaliplatin and TAS-102 in First-line Treatment of Advanced Colorectal Cancer

Who this might be right for
Advanced Colorectal Cancer
The First Affiliated Hospital of Zhengzhou University 20
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07535632
What this trial is testing

SBRT Followed by PD-1 Inhibitor, Bevacizumab and TAS-102 as Third-Line Therapy for Recurrent/Metastatic Colorectal Cancer

Who this might be right for
Colorectal Neoplasms
Shanghai Zhongshan Hospital 58
Testing effectiveness (Phase 2)Active Not RecruitingNCT06699836
What this trial is testing

CLOVER - CCR5-targeting Leronlimab With Oral Chemotherapy and VEGF-inhibitor Enriched Regimen

Who this might be right for
Metastatic Colorectal Cancer (mCRC)
CytoDyn, Inc. 66
Testing effectiveness (Phase 2)Study completedNCT03223779
What this trial is testing

Study of TAS-102 Plus Radiation Therapy for the Treatment of the Liver in Patients With Hepatic Metastases From Colorectal Cancer

Who this might be right for
Colorectal Cancer
Massachusetts General Hospital 52
Testing effectiveness (Phase 2)UnknownNCT03992456
What this trial is testing

Panitumumab, Regorafenib, or TAS-102, in Treating Patients With Metastatic and/or Unresectable RAS Wild-Type Colorectal Cancer

Who this might be right for
Metastatic Colon AdenocarcinomaMetastatic Colorectal CarcinomaMetastatic Rectal Adenocarcinoma+27 more
Academic and Community Cancer Research United 12
Large-scale testing (Phase 3)UnknownNCT03909724
What this trial is testing

Pulsatile High-dose Sunitinib Versus TAS-102 in Patients With Metastatic Colorectal Carcinoma (mCRC)

Who this might be right for
Colorectal CancerMetastasis
Amsterdam UMC, location VUmc 60
Testing effectiveness (Phase 2)WithdrawnNCT05356897
What this trial is testing

Tucatinib Combined with Trastuzumab and TAS-102 for the Treatment of HER2 Positive Metastatic Colorectal Cancer in Molecularly Selected Patients, 3T Study

Who this might be right for
Metastatic Colon AdenocarcinomaMetastatic Colorectal AdenocarcinomaMetastatic Rectal Adenocarcinoma+3 more
Academic and Community Cancer Research United
Not applicableNot Yet RecruitingNCT07371871
What this trial is testing

A Prospective, Single-arm, Exploratory Study of Trifluridine/Tipiracil (TAS-102) Combined With Apatinib as Third-line Therapy for Advanced Gastric Cancer

Who this might be right for
Advanced Gastric Cancer
Anhui Provincial Cancer Hospital 30
Early research (Phase 1)Study completedNCT02602327
What this trial is testing

Tas-102 and Radioembolization With 90Y Resin Microspheres for Chemo-refractory Colorectal Liver Metastases

Who this might be right for
Colon CancerRectal CancerLiver Metastases
University of California, San Francisco 21
Testing effectiveness (Phase 2)Study completedNCT04923529
What this trial is testing

TAS-102 in Patients With Advanced, Refractory Pancreatic Adenocarcinoma

Who this might be right for
Pancreas Cancer
The University of Hong Kong 28
Testing effectiveness (Phase 2)Study completedNCT05481463
What this trial is testing

Surufatinib Combined With TAS-102 in Third-line and Later-line Therapy of Patients With Advanced Pancreatic Cancer

Who this might be right for
Pancreatic Neoplasms
Sun Yat-sen University 22
Not applicableApproved For MarketingNCT02286492
What this trial is testing

Expanded Access Study of TAS-102 in Patients With Metastatic Colorectal Cancer

Who this might be right for
Colorectal Cancer Metastatic
Taiho Oncology, Inc.
Early research (Phase 1)Study completedNCT04074343
What this trial is testing

TAS-102 and Irinotecan in 2L+ Gastric and Gastroesophageal Adenocarcinoma

Who this might be right for
Gastric AdenocarcinomaGastroEsophageal Cancer
University of California, Irvine 20
Large-scale testing (Phase 3)Study completedNCT03520946
What this trial is testing

RAMucirumab in Combination Wth TAS102 vs. TAS102 Alone in Chemotherapy Refractory Metastatic Colorectal Cancer Patients

Who this might be right for
Colorectal Cancer
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest 430
Early research (Phase 1)Study completedNCT04868773
What this trial is testing

Study of Cabozantinib Plus TAS102 in mCRC as Salvage Therapy

Who this might be right for
Colorectal CancerColorectal CarcinomaMetastatic Cancer+1 more
University of California, Irvine 15
Next Page